Welcome to our dedicated page for MyMD Pharmaceuticals news (Ticker: MYMD), a resource for investors and traders seeking the latest updates and insights on MyMD Pharmaceuticals stock.
MyMD Pharmaceuticals, Inc. (DE) (NASDAQ: MYMD) is a clinical-stage biopharmaceutical company that focuses on extending healthy lifespan through the development of innovative therapeutic platforms. The company is committed to addressing serious autoimmune and inflammatory diseases as well as age-related conditions.
Core Therapeutic Platforms:
- MyMD-1: This is a small molecule drug platform that aims to regulate the immunometabolic system by controlling tumor necrosis factor-alpha (TNF-α) and other pro-inflammatory cytokines. MyMD-1 is being developed to treat autoimmune diseases such as multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. Additionally, it targets age-related illnesses, including frailty and sarcopenia. The drug’s oral administration is a significant advantage over existing TNF-α inhibitors, which require injectable forms.
- Supera-CBD: This drug platform is based on a novel synthetic derivative of cannabidiol (CBD) that targets key receptors, including CB2 and opioid receptors, and inhibits monoamine oxidase. Supera-CBD is designed to cater to the rapidly expanding CBD market, addressing conditions such as epilepsy, pain, and anxiety/depression.
Recent Achievements and Current Projects:
MyMD Pharmaceuticals has made significant strides in its clinical trials, particularly with MyMD-1. In a recently completed phase 2 clinical trial, MyMD-1 successfully met its primary endpoints by reducing biomarkers common in chronic inflammatory diseases, such as TNF-α, IL-6, and sTNFR1. The drug also met all secondary endpoints related to safety and tolerability standards. Full study results are expected to be released in 2024.
The company has already submitted and received approval for three Investigational New Drug Applications for MyMD-1, which is now advancing in clinical programs for conditions like sarcopenia, rheumatoid arthritis, and Hashimoto's disease. With a unique oral dosing method, MyMD-1 offers a promising alternative to current TNF-α inhibitors, which typically require infusion or injection.
Partnerships and Future Outlook:
Through strategic partnerships and ongoing research, MyMD Pharmaceuticals aims to pioneer the development of therapies that not only manage symptoms but also extend the healthy lifespan of patients. With its robust pipeline and innovative approaches, MyMD Pharmaceuticals is well-positioned to make a significant impact in the field of autoimmune and age-related disease treatment.
For up-to-date news and developments, visit the StockTitan website.
MyMD Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase 2 trial of MYMD-1, a patented drug aimed at delaying aging. This marks a significant milestone as it is believed to be the only IND application of its kind approved by the FDA. Recruitment for the trial is starting immediately, with efficacy data expected by the end of Q1 2022. MYMD-1 aims to reduce inflammation-related proteins and target root causes of aging, positioning itself for a lucrative market projected to reach over $600 billion by 2025.
MyMD Pharmaceuticals (NASDAQ: MYMD) announced that Dr. Chris Chapman, its President and CMO, will be recognized as the Medical Honoree of 2021 by the Arthritis Foundation at the Commitment to a Cure Gala on October 28, 2021, in Washington, D.C. The gala supports efforts to combat arthritis, a condition affecting over 54 million Americans. MYMD-1, MyMD's lead drug candidate, targets aging and autoimmune diseases like rheumatoid arthritis, with Phase 2 trials set to begin. MYMD-1 aims to regulate pro-inflammatory cytokines, offering potential new treatments amid rising arthritis prevalence.
MyMD Pharmaceuticals (Nasdaq: MYMD) will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021, at 4:30 p.m. ET. The Chief Scientific Officer, Adam Kaplin, M.D., Ph.D., will discuss MYMD-1 and Supera-CBD, two promising drug candidates aimed at treating aging disorders and other conditions. MYMD-1 targets TNF-α to regulate inflammation and is set for two Phase 2 trials. Supera-CBD, a synthetic CBD derivative, aims to address anxiety, pain, and neurodegeneration.
MyMD Pharmaceuticals announced the launch of two simultaneous Phase 2 trials for MYMD-1 this quarter, focusing on its ability to extend healthy lifespan and address COVID-19-associated depression. The trial results will be crucial for evaluating MYMD-1's potential as an immunometabolic regulator. The Company will also present its product pipeline at the Benzinga Rising Stars Conference on October 7, 2021, showcasing MYMD-1 and Supera-CBD, a synthetic CBD derivative targeting chronic pain and addiction.
MyMD Pharmaceuticals (NASDAQ: MYMD) announced promising new data on Supera-CBD, its patented synthetic cannabidiol derivative, demonstrating it is 8,000 times more potent than regular CBD. Supera-CBD targets CB2 receptors, linked to beneficial therapeutic effects such as anxiety and neuroprotection, without the psychotropic effects associated with CB1. The company aims to position Supera-CBD as a prescription drug alternative amidst strong market potential for treating conditions like Alzheimer's and neuropathic pain. Dr. Adam Kaplin and Dr. Chris Chapman highlight the drug's ability to activate CB2 at low non-toxic doses.
MyMD Pharmaceuticals (Nasdaq: MYMD) is set to initiate dosing in a Phase 2 trial for MYMD-1, targeting the reduction of TNF-α to potentially delay aging and extend lifespan. The trial will start in Q4 2021, with interim results expected in Q1 2022. MYMD-1 aims to differentiate itself as the first oral TNF-α inhibitor, addressing chronic inflammation—a key aging factor. The market for aging-related treatments is projected to exceed $600 billion by 2025, underscoring the potential growth for MYMD-1.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) will showcase its development pipeline at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually from September 13-15, 2021. The presentation, accessible on-demand from 7:00 am ET on September 13, will feature Dr. Chris Chapman and Dr. Adam Kaplin discussing MyMD-1 and Supera-CBD. MYMD-1 aims to treat aging, autoimmune diseases, and COVID-19-related conditions, while Supera-CBD targets anxiety, chronic pain, and addiction, progressing toward human trials.
MyMD Pharmaceuticals (Nasdaq: MYMD) announced the issuance of U.S. Patent No. 11,096,933, securing methods for administering MYMD-1 to treat chronic inflammation-related disorders, particularly fibrosis and asthma. This patent marks the thirteenth supporting MYMD-1's development as a treatment for autoimmune and age-related diseases. The compound has shown potential in regulating the immune system and addressing diseases like idiopathic pulmonary fibrosis, which affects nearly 100,000 individuals in the U.S.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) announced the issuance of U.S. Patent No. 11,085,047 for its drug candidate Supera-CBD, aimed at treating substance addiction and neurodegenerative diseases. Supera-CBD, a synthetic cannabidiol derivative, is projected to be significantly more effective than plant-derived CBD in treating conditions such as anxiety and chronic pain. The patent strengthens the company’s intellectual property position, adding to its existing 11 patents for the MYMD-1 drug platform, and supports the advancement towards human clinical trials.
MyMD Pharmaceuticals (Nasdaq: MYMD) announced that its subsidiary, Oravax Medical, is set to initiate clinical trials for an oral COVID-19 vaccine, starting in Israel. This vaccine is designed for both standalone use and as a booster for previously vaccinated individuals. MyMD holds a 13% stake in Oravax and a 2.5% royalty on future net sales. The potential spin-off of Oravax could benefit MyMD shareholders, with Oravax's vaccine being a triple antigen candidate, possibly offering broader protection against mutations. A Phase 2 trial for MyMD's MYMD-1 is also anticipated by Q4 2021.
FAQ
What is the current stock price of MyMD Pharmaceuticals (MYMD)?
What is the market cap of MyMD Pharmaceuticals (MYMD)?
What is MyMD Pharmaceuticals, Inc.?
What are the main therapeutic platforms developed by MyMD Pharmaceuticals?
What is MyMD-1?
What is Supera-CBD?
What recent achievements has MyMD Pharmaceuticals made?
What conditions is MyMD-1 being developed to treat?
How is MyMD-1 administered?
What are the potential benefits of Supera-CBD?
Has MyMD Pharmaceuticals received any regulatory approvals?
What is the future outlook for MyMD Pharmaceuticals?
